tert-butyl N-[2-(2,3-dichlorophenyl)ethyl]carbamate | 928628-88-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl N-[2-(2,3-dichlorophenyl)ethyl]carbamate
• CAS: 928628-88-0
• 化学式: C₁₃H₁₇Cl₂NO₂
• 分子量: 290.189
• InChiKey: GIUNLPDLHFHELY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  tert-butyl N-[2-(2,3-dichlorophenyl)ethyl]carbamate 在 偶氮二异丁腈 、 sodium hydride 作用下， 生成 tert-butyl [2-(2,3-dichlorophenyl)ethyl]{3-[(2-hydroxyethyl)thio]propyl}carbamate
  参考文献：
  名称：

  Design-driven LO: The discovery of new ultra long acting dibasic β2-adrenoceptor agonists

  摘要：

  Starting with the molecular scaffold of the DA(2)/beta(2) dual agonist sibenadet ( Viozan (TM)), a number of molecular changes were incorporated, which were designed to increase the potency and selectivity of the target molecule, and improve its pharmacokinetics. Through this process a novel, high potency, full beta(2)-agonist with high selectivity and long duration capable of being dosed once daily has been discovered. (C) 2011 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2011.05.097
• 作为产物：
  描述：

  二碳酸二叔丁酯 、 2,3-二氯苯乙胺 在 三乙胺 作用下， 生成 tert-butyl N-[2-(2,3-dichlorophenyl)ethyl]carbamate
  参考文献：
  名称：

  Design-driven LO: The discovery of new ultra long acting dibasic β2-adrenoceptor agonists

  摘要：

  Starting with the molecular scaffold of the DA(2)/beta(2) dual agonist sibenadet ( Viozan (TM)), a number of molecular changes were incorporated, which were designed to increase the potency and selectivity of the target molecule, and improve its pharmacokinetics. Through this process a novel, high potency, full beta(2)-agonist with high selectivity and long duration capable of being dosed once daily has been discovered. (C) 2011 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2011.05.097

文献信息

• [EN] PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS<br/>[FR] PRÉPARATION DE DÉRIVÉS DE COMPOSÉS 1,2-DIAMINOHÉTÉROCYCLIQUES SUBSTITUÉS ET LEUR UTILISATION EN TANT QU'AGENTS PHARMACEUTIQUES
  申请人：AVELOS THERAPEUTICS INC

  公开号：WO2022260441A1

  公开（公告）日：2022-12-15

  This invention relates to compounds which are microtubule associated serine/threonine-like kinase (MASTL) inhibitors and the use of the compounds in the treatment of diseases and medical conditions mediated by MASTL, for example in the treatment of cancer and other target related diseases.

  本发明涉及一种微管相关丝氨酸/苏氨酸样激酶（MASTL）抑制剂化合物及其在治疗由MASTL介导的疾病和医学状况中的应用，例如在治疗癌症和其他相关疾病中的应用。
• Design-driven LO: The discovery of new ultra long acting dibasic β2-adrenoceptor agonists
  作者：Stephen Connolly、Lilian Alcaraz、Andrew Bailey、Elaine Cadogan、Jadeen Christie、Anthony R. Cook、Adrian J. Fisher、Stephen Hill、Alexander Humphries、Anthony H. Ingall、Zoe Kane、Stuart Paine、Garry Pairaudeau、Michael J. Stocks、Alan Young

  DOI：10.1016/j.bmcl.2011.05.097

  日期：2011.8

  Starting with the molecular scaffold of the DA(2)/beta(2) dual agonist sibenadet ( Viozan (TM)), a number of molecular changes were incorporated, which were designed to increase the potency and selectivity of the target molecule, and improve its pharmacokinetics. Through this process a novel, high potency, full beta(2)-agonist with high selectivity and long duration capable of being dosed once daily has been discovered. (C) 2011 Published by Elsevier Ltd.